More Clinical Articles


VIDEO: Cancer survivor Jack Whelan speaks on how pharma can become more patient centric

Izzy Gladstone, (Jul 14, 2014)

Jack Whelan, ePatient and clinical trial proponent on how pharma needs to push the regulatory boundaries to fully engage with the patient and how a strict regulatory environment is hampering meaningful dialogue between pharma and the patient

Slashing the cost of clinical trials

Zuzanna Fimińska, (Jun 10, 2014)

It is a truth universally acknowledged that in this tough payer climate, pharma must slash costs. Software companies offer opportunities to streamline the clinical trial process from design to analysis, promising to save the industry at least US$3.7billion across phase II and phase III trials.
Access and Evidence

Big Data Will Make Clinical Trials Obsolete

Zuzanna Fimińska, (Apr 24, 2014)

Clinical trials as we know it are over. Their annual cost is unsustainable and solutions that curtail these expenses must be put in place. Luckily, big data offers unprecedented opportunities that will revolutionize research.

5 tips on how to facilitate clinical trial recruitment

Zuzanna Fimińska, (Apr 8, 2014)

Clinical trials are essential to medical research. Bringing new drugs to the market depends on the ability of research organizations and drug companies to rigorously test and validate their work, but finding people willing to participate is notoriously difficult.

I Will Survive: Beating the Odds with Clinical Trials

Zuzanna Fimińska, (Mar 11, 2014)

When faced with life-threatening illness we all want effective treatment, but very few look for it outside of standard therapies. Participating in clinical trials offers an opportunity to get exposed to cutting-edge technologies that might prove life-saving.
Access and Evidence

Real World Data: Real World Opportunities

Zuzanna Fimińska, (Feb 27, 2014)

Supplementing information gathered in randomised clinical trials (RCT), optimising RCT design, and streamlining R&D are just some of the opportunities that come with big data, but successful implementation of RWD depends on breaking down data silos, and devising an optimum strategy.
Access and Evidence

Real World Data: Promises and Challenges

Zuzanna Fimińska, (Feb 18, 2014)

Big data, big promises, but getting the complete picture needs multiple sources of information. Real World Data (RWD), randomized clinical trials (RCTs), and small-scale, focus-group-based surveys are not members of opposite teams, but pieces of the same puzzle.

Using Electronic Patient-Reported Outcomes (ePRO) for the First Time: Lessons Learned

Darja Turner, (Dec 19, 2013)

The importance of patient-reported outcomes (PROs) is evidenced by their increased use in clinical trials and in drug and device label claims. Here Darja Turner shares her experiences using an electronic PRO tool for the first time.

The Pharma/University Partnership is Vital to Drug Discovery

Zuzanna Fimińska, (Aug 19, 2013)

Most major academic institutions around the world now have an alliance with the industry. By reaching out to communities rich in scientific talent and creativity, drug manufacturers hope to identify novel molecules and new uses for the old ones.

A Healthcare Revolution: Virtual Innovation at Full Speed

Louise Kelly, (Aug 6, 2013)

A number of players are working on combining patient health information with their own innovative virtual models, fine-tuning relevant the data for effective use. Where clinical trials may not be possible – or effective – these tools could become a viable alternative.